(OA15) Clinical Outcomes of Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immunotherapy

Several clinical trials of anti-PD-1 and CTLA-4 therapies have demonstrated a clinical benefit in patients with melanoma brain metastases (MBMs) and a low incidence of neurologic adverse events. The combined effect of these immunotherapies and stereotactic radiosurgery (SRS) on toxicity and survival in patients with MBMs is not well understood. We retrospectively reviewed patients treated with anti-PD-1, anti-CTLA-4 therapy or the combination and SRS to report on these outcomes.

https://ift.tt/2HK5wW7